arrow
J

J William L Brown

University of Melbourne
H指数:18
被引数:2,332

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries

在四国欧洲国家进行的阿仑单抗治疗多发性硬化风险最小化措施依从性研究

2026-05-210
PRE
The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy

剑桥髓鞘修复中心试验二(CCMR Two):一项关于评估二甲双胍和氯马斯汀联合应用在已接受疾病修正治疗的活动性复发-缓解型多发性硬化患者中促进髓鞘再生的能力的2a期、随机、双盲、安慰剂对照临床试验方案

2025-12-080
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

克拉屈滨与芬戈莫德,那他珠单抗,ocrelizumab和阿仑单抗在复发缓解型多发性硬化症中的疗效比较

2024-08-010
PRE
A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis
2023-10-1911
OAAI
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

早期非残疾复发是复发缓解型多发性硬化症患者残疾积累的重要预测因素

2023-02-279
OAAI
Remyelination varies between and within lesions in multiple sclerosis following bexarotene
2022-09-1711
OA